PollyANiravathMD

Oncology • Houston, TX

Assistant Professor, Breast Center, Baylor College of Medicine

Join to view full profile

Dr. Niravath is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Niravath's full profile

Already have an account?

Office
6445 Main St
# Opc
Houston, TX 77030
Phone+1 713-441-9948

Fax+1 713-441-8791

Education & Training

Baylor College of MedicineFellowship, Hematology and Medical Oncology, 2008 - 2011
Baylor College of MedicineResidency, Internal Medicine, 2005 - 2008
University of California, Irvine, School of MedicineClass of 2005

Certifications & Licensure

TX State Medical License 2007 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer Start of enrollment: 2007 Dec 01
Completed
Phase 2
HKI-272 for HER2-Positive Breast Cancer and Brain Metastases Start of enrollment: 2012 Feb 01
Active, not recruiting
Phase 2
Treatment for Joint Pains Due to Aromatase Inhibitor Therapy in Breast Cancer Start of enrollment: 2013 Oct 01
Withdrawn
Phase 2
REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy Start of enrollment: 2013 Sep 01
Recruiting
Phase 2
Scalp Cooling to Prevent Chemo-induced Hair Loss Start of enrollment: 2014 May 15
Active, not recruiting
Not Applicable
High Dose Vitamin D vs Standard Dose Vitamin D Study Start of enrollment: 2013 Dec 01
Terminated
Phase 2
CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer Start of enrollment: 2014 Jun 01
Terminated
Phase 1
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) Start of enrollment: 2023 Jan 12
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

3 citations
Pulmonary arterial hypertension in breast cancer patients on HER2-targeted therapy: a review of FDA Adverse Events Reporting System data.
Godsfavour Umoru, Matthew Taitano, Sarah Beshay, Polly A. Niravath, Sandeep Sahay
ERJ Open Research. 2020-07-20
49 citations
A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer.
Andrew W Chung, Kartik Anand, Ann C Anselme, Alfred A Chan, Nakul Gupta
Science Translational Medicine. 2021-12-15
17 citations
Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy.
Kartik Anand, Tejal Patel, Polly A. Niravath, Angel Rodriguez, Jorge Darcourt
Scientific Reports. 2021-01-08

Lectures

Current Treatment Strategies for Metastatic Breast Cancer
2013 International Symposium, San Antonio, Texas, USA
Current Treatment Strategies for Metastatic Breast Cancer
San Antonio Breast Cancer Symposium, 2013 International Symposium, San Antonio, Texas, USA

Press Mentions

The Eating and Drinking Habits That Affect Your Risk of Breast CancerOctober 11th, 2022
The Eating and Drinking Habits That Affect Your Breast Cancer RiskOctober 11th, 2022
Study Shows the Pain of Carrying Debt Can Be Physical, TooOctober 4th, 2021
Join now to see all